Background: Serum pepsinogen II (sPGII) levels are known to increase during Helicobacter pylori infection. Aim: To assess H. pylori infection and success of H. pylori therapy by means of sPGII levels. Methods: sPGII l...Background: Serum pepsinogen II (sPGII) levels are known to increase during Helicobacter pylori infection. Aim: To assess H. pylori infection and success of H. pylori therapy by means of sPGII levels. Methods: sPGII levels were determined in 156 H. pylori-positive and 157 H. pylori-negative consecutive patients with dyspeptic symptoms. Additionally, sPGII determination was performed in 70 H. pylori-positive patients 2 months after H. pylori eradication therapy. In 29 of these 70 patients, gastroscopy was performed to evaluate the effect of H. pylori therapy on gastric activity. Results: H. pyloripositive subjects demonstrated a significantly higher mean of sPGII levels than H. pylori-negative subjects (16.8 ±7.4 vs. 8.6 ±3.7 μg/l; p < 0.001). The best sPGII cut-off for predicting H. pylori infection was 9.93 μg/l (sensitivity 83%, specificity 73%). The best cut-off values to evaluate success of therapy were: sPGII of 9.47 μg/l, a sPGII variation level (difference between baseline and after therapy) of 4.54 μg/l, and a sPGIIΔvalue (sPGII variation divided by sPGII before therapy) of 25%(sensitivity 93%, specificity 91%). Conclusions: sPGII levels may be used as a reliable marker of H. pylori infection in the initial diagnosis as well as to evaluate H. pylori eradication and subsequent changes in gastric inflammation.展开更多
目的建立1套简易ABO基因定型试剂盒。方法利用PCR-ASP(Allele-specific primer)法对9例正反定型不符合标本进行基因定型。结果2例为AB基因型,1例为O1vO1v基因型。另外还有3例B(A)/O基因型、3例cisAB/O基因型。结论该试剂盒利用Allele-sp...目的建立1套简易ABO基因定型试剂盒。方法利用PCR-ASP(Allele-specific primer)法对9例正反定型不符合标本进行基因定型。结果2例为AB基因型,1例为O1vO1v基因型。另外还有3例B(A)/O基因型、3例cisAB/O基因型。结论该试剂盒利用Allele-specific primer PCR(PCR-ASP)法可正确鉴定出A、B、O等位基因及一些ABO亚型等位基因,如cisAB和B(A)血型等位基因。这些标本类型其实在血站或医院血库的日常工作中会经常遇到,提示该试剂盒具有较好临床应用性。血清学凝集试验是检测血型抗原物质的金标准,但存有缺陷。展开更多
文摘Background: Serum pepsinogen II (sPGII) levels are known to increase during Helicobacter pylori infection. Aim: To assess H. pylori infection and success of H. pylori therapy by means of sPGII levels. Methods: sPGII levels were determined in 156 H. pylori-positive and 157 H. pylori-negative consecutive patients with dyspeptic symptoms. Additionally, sPGII determination was performed in 70 H. pylori-positive patients 2 months after H. pylori eradication therapy. In 29 of these 70 patients, gastroscopy was performed to evaluate the effect of H. pylori therapy on gastric activity. Results: H. pyloripositive subjects demonstrated a significantly higher mean of sPGII levels than H. pylori-negative subjects (16.8 ±7.4 vs. 8.6 ±3.7 μg/l; p < 0.001). The best sPGII cut-off for predicting H. pylori infection was 9.93 μg/l (sensitivity 83%, specificity 73%). The best cut-off values to evaluate success of therapy were: sPGII of 9.47 μg/l, a sPGII variation level (difference between baseline and after therapy) of 4.54 μg/l, and a sPGIIΔvalue (sPGII variation divided by sPGII before therapy) of 25%(sensitivity 93%, specificity 91%). Conclusions: sPGII levels may be used as a reliable marker of H. pylori infection in the initial diagnosis as well as to evaluate H. pylori eradication and subsequent changes in gastric inflammation.
文摘目的建立1套简易ABO基因定型试剂盒。方法利用PCR-ASP(Allele-specific primer)法对9例正反定型不符合标本进行基因定型。结果2例为AB基因型,1例为O1vO1v基因型。另外还有3例B(A)/O基因型、3例cisAB/O基因型。结论该试剂盒利用Allele-specific primer PCR(PCR-ASP)法可正确鉴定出A、B、O等位基因及一些ABO亚型等位基因,如cisAB和B(A)血型等位基因。这些标本类型其实在血站或医院血库的日常工作中会经常遇到,提示该试剂盒具有较好临床应用性。血清学凝集试验是检测血型抗原物质的金标准,但存有缺陷。
